WO2022177250A2 - Organoïdes de cancer de haute pureté et leur procédé de construction - Google Patents

Organoïdes de cancer de haute pureté et leur procédé de construction Download PDF

Info

Publication number
WO2022177250A2
WO2022177250A2 PCT/KR2022/002183 KR2022002183W WO2022177250A2 WO 2022177250 A2 WO2022177250 A2 WO 2022177250A2 KR 2022002183 W KR2022002183 W KR 2022002183W WO 2022177250 A2 WO2022177250 A2 WO 2022177250A2
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
organoids
anticancer
patient
present
Prior art date
Application number
PCT/KR2022/002183
Other languages
English (en)
Korean (ko)
Other versions
WO2022177250A3 (fr
Inventor
남은지
설향숙
최은혜
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Publication of WO2022177250A2 publication Critical patent/WO2022177250A2/fr
Publication of WO2022177250A3 publication Critical patent/WO2022177250A3/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Definitions

  • the present invention relates to a high-purity cancer organoid, and a method for preparing the same.
  • targeted therapies are the core of patient-specific anticancer treatment research in that they can dramatically increase the response rate to anticancer drugs in terminal cancer patients, minimize the side effects of anticancer drugs, and predict the cancer response to the treatment with molecular signals. can do.
  • organoids for testing the response before actually administering a patient-specific targeted therapy to a patient has many limitations.
  • the cancer organoids in the body mimic the environment of the cancer tissue, but normal cells in the periphery are collected together in the process of extracting the cancerous tissue from the patient for the manufacture of cancer organoids. Accordingly, during organoid culture, normal organoids other than cancer organoids invade and overgrowth, thereby inhibiting the growth of cancer organoids. In order to suppress this, the prior art has artificially separated and cultured normal organoids and cancer organoids under a microscope.
  • the present invention is to solve the above problems, and relates to a method for selectively inhibiting growth of only normal cells in the preparation of cancer organoids.
  • the present invention is expected to be widely used in the medical field, such as improving the prognosis of cancer patients, since it is possible to prepare pure cancer organoids that are not contaminated by normal cells.
  • the present invention has been devised to solve the problems in the prior art, and relates to a high-purity cancer organoid, and a method for manufacturing the same.
  • cancer is characterized by uncontrolled cell growth, and by such abnormal cell growth, a cell mass called a tumor is formed, penetrates into surrounding tissues, and in severe cases, into other organs of the body. It is said to be transferable. Scientifically, it is also called a neoplasm. Cancer is an intractable chronic disease that in many cases cannot be cured fundamentally even if it is treated with surgery, radiation, and chemotherapy but causes pain and ultimately death. and external factors. It is not known exactly how normal cells are transformed into cancer cells, but it is known that a significant number of cancers are affected by external factors such as environmental factors. Internal factors include genetic factors and immunological factors, and external factors include chemicals, radiation, and viruses.
  • cancer cells exhibit different genetic characteristics from normal cells. Genes related to the development of cancer are called oncogenes, and genes that suppress tumor development are called tumor suppressor genes. Cancer occurs when the balance between oncogenes and tumor suppressor genes is disrupted by the intrinsic or extrinsic factors described above. Specifically, cancer occurs when an oncogene is overexpressed or when a tumor suppressor gene fails to function due to mutation or the like.
  • Representative oncogenic genes include c-myc (Proto-oncogene bHLH transcription factor), c-src (Proto-oncogene tyrosine-protein kinase), NOTCH (Notch Receptor), FGFR (Fibroblast Growth Factor Receptor), EGFR (Epidermal Growth Factor Receptor) ) and the like, and representative tumor suppressor genes include transforming growth factor-beta (TGF- ⁇ ) and tumor protein p53 (TP53).
  • TGF- ⁇ tumor growth factor-beta
  • TP53 tumor protein p53
  • cancers include oral cancer, liver cancer, stomach cancer, colon cancer, breast cancer, lung cancer, bone cancer, pancreatic cancer, skin cancer, head cancer, cervical cancer, skin cancer, cervical cancer, ovarian cancer, colorectal cancer, small intestine cancer, rectal cancer, fallopian tube carcinoma, and anal cancer.
  • the cancer of the present invention is preferably a female cancer (breast cancer, cervical cancer, ovarian cancer, fallopian tube carcinoma, endometrial carcinoma, vaginal carcinoma, thyroid cancer, parathyroid cancer), but is not limited thereto.
  • cancer tissue refers to a set of cancer cells for examination or disposal separated from the human body by incision or fine needle method when cancer incision is required for the purpose of benefiting the human body in a cancer patient do.
  • the cancer tissue may be used to prepare an organoid for a specific cancer tissue and develop a customized therapeutic agent for the purpose of benefiting the human body of a cancer patient.
  • metastasis refers to cancer cells leaving a primary organ and moving to another organ.
  • the spread of cancer to other parts of the body is largely divided into growth of cancer tissue from the primary cancer and directly infiltrating surrounding organs, and distant metastasis along blood vessels or lymphatic vessels to other distant organs.
  • the rate or pattern of metastasis may vary depending on the intrinsic nature of cancer, and may be regulated by suppressing the expression of a gene related to metastasis or suppressing the protein activity of the gene.
  • organoid refers to a structure made by culturing or recombining cells isolated from stem cells or organ cells, and maintaining the shape of the tissue in vitro, artificial organs, bio-organs, It can be interpreted in the same sense as mini-organ, spheroid, spheroid, or embryoid body.
  • the organoid is a cancer organoid and is characterized by being composed of cancer cells.
  • porous medium refers to a liquid that is initially liquid and can be solidified under various conditions, and the conditions include temperature, light, pH, pressure, vibration, and the like.
  • a porous medium that is liquid at high temperatures may gel at low temperatures.
  • the porous medium may be a material such as a hydrogel or a porous membrane.
  • the hydrogel may be a natural or synthetic polymer material.
  • the hydrogel may include collagen, fibrin, agarose, agar, matrigel, alginate, gelatin, and the like.
  • Microgel is an artificially synthesized extracellular matrix that is commercially sold, and is composed of laminin, collagen type IV, heparin sulfate proteoglycan and entactin/nidogen. , but is not limited thereto.
  • diagnosis refers to confirming the presence or characteristics of a pathological state, and for the purpose of the present invention, diagnosis is to determine whether or not cancer has occurred, progressed, and metastasized.
  • Cancer can be diagnosed by visual or cytological confirmation of tissue from a patient with cancer onset or suspected of metastasis. ( ⁇ ), secretion, bile, pharyngeal mucus, urine ( ⁇ ), bile, feces, etc.) a method using a cancer-associated antibody, a method for directly detecting a cancer-related protein in the sample, or a method for encoding a cancer-related protein Cancer can be diagnosed by a method of directly detecting a nucleic acid.
  • Diagnostic methods using antigen-antibody binding or direct detection of cancer-associated proteins include Western blot, ELISA (enzyme linked immunosorbent assay), radioimmunoassay (RIA), radioimmunodiffusion, octero Ouchterlony immunodiffusion method, rocket immunoelectrophoresis, tissue immunostaining, Immunoprecipitation Assay, Complement Fixation Assay, Fluorescence Activated Cell Sorter (FACS), Protein Chip ( protein chip), but is not limited thereto, and methods for directly detecting a nucleic acid encoding a cancer-related protein include reverse transcription polymerase reaction (RT-PCR), competitive reverse transcription polymerase reaction (Competitive RT-PCR), real-time Reverse transcription polymerase reaction (Real-time RT-PCR), RNase protection assay (RPA; RNase protection assay), Northern blotting (Northern blotting) or DNA chip, but is not limited thereto.
  • RT-PCR reverse transcription polymerase reaction
  • screening refers to selecting a substance having a specific desired property from a candidate group consisting of several substances by a specific manipulation or evaluation method.
  • the screening of the present invention is to treat the cancer organoid according to the present invention with an anticancer candidate material, and when the size of cancer tissue is reduced or metastasis is inhibited by the anticancer candidate material, the candidate material is used as a cancer treatment agent or a cancer metastasis inhibitor.
  • the term "anticancer drug candidate” refers to an unknown substance used in screening to test whether it has inhibitory activity against the growth or metastasis of tumor tissue.
  • the candidate substances include, but are not limited to, chemicals, peptides, proteins, antibodies, and natural extracts.
  • Candidates analyzed by the screening methods of the present invention are single compounds or mixtures of compounds (eg, natural extracts or cell or tissue cultures). Candidates can be obtained from libraries of synthetic or natural compounds. Methods for obtaining libraries of such compounds are known in the art. Synthetic compound libraries are commercially available from Maybridge Chemical Co. (UK), Comgenex (USA), Brandon Associates (USA), Microsource (USA) and Sigma-Aldrich (USA), and natural compounds libraries are available from Pan Laboratories (USA).
  • Candidate substances can be obtained by various combinatorial library methods known in the art, for example, biological libraries, spatially addressable parallel solid phase or solution phase libraries, deconvolution It can be obtained by the required synthetic library method, the 1-bead 1-compound library method, and the synthetic library method using affinity chromatography selection. Methods for synthesizing molecular libraries are described in DeWitt et al., Proc. Natl. Acad. Sci. U.S.A. 90, 6909, 1993; Erb et al. Proc. Natl. Acad. Sci.
  • alkylating agents highly reactive substances with the ability to introduce an alkyl group R-CH 2 to a certain compound. When acted on cells, most of them react with N7 of guanine in DNA to modify the DNA structure, It causes chain cutting [ ⁇ ] to show anticancer and cytotoxic effects.
  • Drugs belonging to this category include: 1 Nitrogen mustard: Nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, etc. 2 Ethyleneimine: thiotepa 3 Alkylsulfonate: Busulfan 4 Tri Azine-hydrazine: DTIC (dacarbazine), procarbazine 5 Nitrosourea: BCNU, CCNU, methyl-CCNU, etc.
  • Antimetabolites Drugs belonging to this group inhibit the metabolic process necessary for the proliferation of cancer cells.
  • 1 Folate derivative Mesotrexate (MTX) 2
  • Purine derivatives 6-mercaptopurine (6-MP), 6-thioguanine 3
  • Pyrimidine derivatives 5-fluorouracil and cytarabine.
  • Antibiotics ( ⁇ : antibiotics): Adriamycin, daunorubicin, bleomycin, mitomycin-C, actinomycin-D, etc. are among the antibiotics produced by bacteria that exhibit anticancer action.
  • Mitosis inhibitors ( ⁇ : vinca alkaloids): These drugs are mitotic-specific drugs that stop cell division in the metaphase of mitosis. vincristine, vinblastine, VP-16-213 and VM-26.
  • Hormones Some types of cancer can be treated by administering hormones. When male hormones are used, breast cancer, female hormones are effective against prostate cancer, and progesterone is effective against endometrial cancer. is used for the treatment of acute lymphoblastic leukemia or lymphoma, and for breast cancer, tamoxifen, an anti-female hormone, is used.
  • administration means introducing the composition to the patient by any suitable method, and the administration route of the composition may be administered through any general route as long as it can reach the target tissue.
  • Oral administration, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, intranasal administration, intrapulmonary administration, rectal administration, intraperitoneal administration, intraperitoneal administration, intrathecal administration may be made, but is not limited thereto.
  • the effective amount to be administered is the type of disease, the severity of the disease, the type and content of the active ingredient and other ingredients contained in the composition, the type of formulation and the patient's age, weight, general health status, sex and diet, administration time, It can be adjusted according to various factors including the route of administration and secretion rate of the composition, duration of treatment, and drugs used concurrently.
  • the therapeutic pharmaceutical composition can be administered into the body in an amount of 50ml to 500ml at a time, 0.1ng/kg-10mg/kg in the case of a compound, and 0.1ng/kg/kg in the case of a monoclonal antibody to the protein It may be administered at a dose of kg-10 mg/kg.
  • the administration interval may be 1 to 12 times a day, and if administered 12 times a day, it may be administered once every 2 hours.
  • anticancer peptides or nucleic acids including antibodies or siRNAs, may be administered alone or with other therapies known in the art, for example, chemotherapeutic agents, radiation and surgery for the treatment of desired cancer.
  • the peptides and nucleic acids of the present invention can be administered in admixture with other treatments designed to enhance the immune response, for example adjuvants or cytokines (or nucleic acids encoding cytokines) as well known in the art. .
  • Other standard delivery methods may be used, such as biolistic delivery or ex vivo treatment.
  • antigen-presenting cells for example, antigen-presenting cells (APCs), dendritic cells, peripheral blood mononuclear cells, or bone marrow cells can be obtained from a patient or an appropriate donor and activated ex vivo with the present immune composition and then administered to the patient.
  • APCs antigen-presenting cells
  • dendritic cells dendritic cells
  • peripheral blood mononuclear cells peripheral blood mononuclear cells
  • bone marrow cells can be obtained from a patient or an appropriate donor and activated ex vivo with the present immune composition and then administered to the patient. have.
  • step (a) dissociating cells from the cancer tissue isolated from the subject; (b) mixing and seeding the cell aggregate (pettet) obtained after centrifugation with a porous medium; And, (c) inhibiting the growth of normal cells; culturing in a culture medium comprising; provides a method for producing cancer organoids comprising; dissociation in step (a) is performed with collagenase It provides a method for producing a cancer organoid, wherein the porous medium in step (b) provides a method for producing a cancer organoid that is a hydrogel or a membrane, wherein the hydrogel is collagen, Fibrin (fibrin), agarose (agarose), agar (agar), matrigel (matrigel), alginate (alginate), and production of cancer organoids that are at least one selected from the group consisting of gelatin (gelatin) It provides a method for producing a cancer organoid, wherein the inhibition of normal cell growth in step (c) is
  • a culture medium for cancer organoid culture comprising an anticancer agent, wherein the anticancer agent is an Epidermal Growth Factor Receptor-Tyrosine kinase inhibitor (EGFR-TKI). It provides a culture medium for culturing cancer organoids, and the anticancer agent provides a culture medium for culturing cancer organoids that is gefitinib or erlotinib.
  • EGFR-TKI Epidermal Growth Factor Receptor-Tyrosine kinase inhibitor
  • a cancer organoid treated with an anticancer agent wherein the anticancer agent is an Epidermal Growth Factor Receptor-Tyrosine kinase inhibitor (EGFR-TKI). It provides, and the anticancer agent provides a cancer organoid that is gefitinib (gefitinib), or erlotinib (Erlotinib).
  • EGFR-TKI Epidermal Growth Factor Receptor-Tyrosine kinase inhibitor
  • a tyrosine kinase inhibitor Edpidermal Growth Factor Receptor-Tyrosine kinase Inhibitor
  • the step of treating an anticancer candidate substance to the cancer organoid treated with an anticancer agent comprising the step of selecting the candidate substance as a target patient's cancer therapeutic agent
  • the selection of the cancer treatment method is chemotherapy, radiation therapy, surgical therapy, immune cell therapy, or a combination thereof provides an information providing method for the selection of a patient-specific cancer treatment method
  • the anticancer agent Epidermal Growth Factor Receptor-Tyrosine kinase inhibitor (Epidermal Growth Factor Receptor-Tyrosine kinase Inhibitor; EGFR-TKI) provides an information providing method for selecting a patient-specific cancer treatment method
  • the anticancer agent gefitinib (gefitinib) , or erlotinib (Erlotinib) provides an information providing method for the selection of a patient
  • the present invention is designed to solve the conventional problem of inhibiting the growth of cancer organoids by intrusion and overproliferation of normal cells other than cancer cells when preparing cancer organoids. it's about
  • the high-purity cancer organoid prepared by the method of the present invention can accurately predict drug reactivity in cancer patients, it is expected to be widely used in the medical field, such as improving the prognosis of cancer patients.
  • FIG. 1 shows the organoid production results when culturing cancer organoids continuously in EM culture medium, or in gefitinib culture medium for 2 weeks, 4 weeks, or 8 weeks according to an embodiment of the present invention.
  • Figure 2 is, according to an embodiment of the present invention, when the cancer organoids are continuously cultured in the EM culture medium, or the organoid production results when cultured for 2 weeks, 4 weeks, or 8 weeks with the gefitinib culture medium, and the The results of H&E staining of organoids are shown.
  • 3 to 5 are, according to an embodiment of the present invention, A83-01 is removed from the EM culture medium and TGF - ⁇ is added (-A83-01 + TGFb), Nutlin is added to the culture medium ( + Nutlin), or shows the results of culturing cancer organoids in gefitinib culture.
  • T denotes a cancer organoid
  • N denotes a normal organoid.
  • FIG. 6 shows a total of 195 genes to be analyzed for genetic variation according to an embodiment of the present invention.
  • FIG. 7 is a diagram showing the results of analysis of genetic mutations in a patient-derived cancer tissue sample according to an embodiment of the present invention.
  • FIG. 8 is a diagram showing the results of gene mutation analysis in cancer organoids cultured for 8 weeks in EM culture medium according to an embodiment of the present invention.
  • FIG. 9 is a diagram showing the results of gene mutation analysis in cancer organoids cultured for 8 weeks in gefitinib culture medium according to an embodiment of the present invention.
  • the patient-derived cancer cells were cultured based on the EM culture medium, but when normal cell contamination was confirmed during culture (usually on day 3-4), it was replaced with a gefitinib culture medium.
  • the gefitinib culture medium was treated for 2 weeks, 4 weeks, or 8 weeks or more, it was confirmed that the distribution of cancer organoids proportionally increased according to the treatment period.
  • a control group for cancer organoids was prepared by preparing endometrial normal organoids.
  • the obtained tissue was washed with RPMI 1640 culture medium, pulverized into small units, and 2 mg/ml collagenase type I 5 ml was added and stirred at 37° C. for 30 minutes. . Then, the collagenase was neutralized with 20 ml of RPMI1640, and centrifuged at 1000 rpm for 5 minutes to obtain a cell aggregate (pellet). When blood was mixed, the cell aggregates were diluted with 1 ml of distilled water and reacted on ice for 3 minutes, after which 9 ml of RPMI1640 culture solution was added and centrifuged to re-obtain cell aggregates.
  • the obtained petlets were diluted in 1 ml of RPMI1640 culture solution, counted, and centrifuged again to mix the cell aggregate with Matrigel (15 ⁇ l/well), and then incubated at 37° C. for 1 hour after dispensing in a 24-well plate. Then, a customized culture medium (complete medium) was added and cultured in a 37° C. CO 2 incubator. The culture medium was freshly replaced every 2-3 days.
  • the customized culture medium is applied as a basic EM culture medium, and when normal cell contamination is confirmed during culture (usually on day 3-4), it was replaced with a gefitinib culture medium.
  • the composition of the EM culture solution and the gefitinib culture solution is shown in Table 1 and Table 2, respectively.
  • Agent name Final concentration ADF (Advanced DMEM/F12, -4°C) up to 50 mL Antibiotic-Antimycotic (100X, 100ml) One% R-spondin1 conditioned medium (R-spondin CM, stock : 2 ⁇ g/mL) 10% B-27 supplement (50X -20°C) - B One% N-2 supplement (100x, 50ml) One% L-glutamine (200Mm, 100ml) 2 mM N-acetyl-l-CYSTEIN (5 g, in water) 1.25mM Human EGF (Hegf STOCK: 10ug/ml) 50ng/ml Nicotinamide-Ni (stock 1M) 10 mM human Noggin - N (stock con.
  • ADF Advanced DMEM/F12, -4°C
  • Agent name Final concentration ADF (Advanced DMEM/F12, -4°C) up to 50 mL Antibiotic-Antimycotic (100X, 100ml) One% R-spondin1 conditioned medium (R-spondin CM, stock : 2 ⁇ g/mL) 10% B-27 supplement (50X -20°C) - B One% N-2 supplement (100x, 50ml) One% L-glutamine (200Mm, 100ml) 2 mM N-acetyl-l-CYSTEIN (5 g, in water) 1.25mM Nicotinamide-Ni (stock 1M) 10 mM human Noggin - N (stock con.
  • ADF Advanced DMEM/F12, -4°C
  • 1 and 2 show the organoid production results when the cancer organoids were continuously cultured in the EM culture medium or cultured for 2 weeks, 4 weeks, or 8 weeks with the gefitinib culture medium.
  • the gefitinib culture medium was treated for 2 weeks, 4 weeks, or 8 weeks or more, it was confirmed that the distribution of cancer organoids proportionally increased according to the treatment period.
  • a total of 195 gene mutations were identified in patient-derived cancer tissue samples, cancer organoids cultured for 8 weeks in EM culture medium, or cancer organoids cultured for 8 weeks in gefitinib culture medium.
  • Cancer tissue samples derived from the patient and cancer organoids cultured for 8 weeks in EM culture medium have a mixed state of cancer cells and normal cells, and cancer organoids cultured for 8 weeks in gefitinib culture medium contain only cancer cells. After confirming that, the test was carried out.
  • a total of 195 genes to be analyzed are shown in FIG. 6 , and the analysis results of each group are shown in FIGS. 7 to 9 .
  • IDH2 Isocitrate dehydrogenase [NADP]2)
  • FGFR1 Fibroblast Growth Factor Receptor 1
  • NOTCH3 Notch Receptor 3
  • ATM serine/threonine kinase
  • cancer organoids embody the environment of cancer tissue in the body, but normal organoids other than cancer organoids invade and overgrowth, thereby inhibiting the growth of cancer organoids.
  • the present invention is expected to be widely used in the medical field, such as improving the prognosis of cancer patients, since it is possible to prepare pure cancer organoids that are not contaminated by normal cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Afin de prédire la réactivité à un médicament chez des patients atteints d'un cancer, il est préférable que les organoïdes de cancer reflètent l'environnement de tissus cancéreux in vivo tel quel. Cependant, le problème qui se pose est que, pendant que les organoïdes de cancer sont cultivés, les organoïdes normaux s'introduisent et se développent, entrainant ainsi l'inhibition de la croissance des organoïdes du cancer. Le but de la présente invention est de résoudre le problème susmentionné et concerne des organoïdes de cancer purs non contaminés par des cellules normales, ainsi qu'un procédé de construction associé. Selon le procédé de construction de la présente invention, les organoïdes de cancer reproduisent l'environnement de cancer in vivo tel quel, ce qui permet un traitement précis adapté au patient. L'utilisation des organoïdes de cancer devrait être d'une grande efficacité dans le domaine médical, en améliorant un pronostic de patients atteints d'un cancer, par exemple, etc.
PCT/KR2022/002183 2021-02-16 2022-02-16 Organoïdes de cancer de haute pureté et leur procédé de construction WO2022177250A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0020489 2021-02-16
KR20210020489 2021-02-16

Publications (2)

Publication Number Publication Date
WO2022177250A2 true WO2022177250A2 (fr) 2022-08-25
WO2022177250A3 WO2022177250A3 (fr) 2022-10-13

Family

ID=82931504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/002183 WO2022177250A2 (fr) 2021-02-16 2022-02-16 Organoïdes de cancer de haute pureté et leur procédé de construction

Country Status (2)

Country Link
KR (1) KR20220117170A (fr)
WO (1) WO2022177250A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112172A1 (fr) * 2015-01-07 2016-07-14 Dana-Farber Cancer Institute, Inc. Culture cellulaire microfluidique de sphéroïdes de cellules tumorales dérivées de patient
PL3580333T3 (pl) * 2017-02-07 2021-08-02 Corning Incorporated Wysokosprawna analiza 3d dla naprowadzania na cel, migracji i cytotoksyczności wobec nowotworu komórki odpowiedzi immunologicznej i leku
KR102152492B1 (ko) * 2017-08-14 2020-09-04 울산대학교 산학협력단 3차원 폐암 오가노이드 배양 방법 및 이를 이용한 환자 유래 이종이식 동물모델의 제조 방법
KR102205179B1 (ko) * 2019-06-19 2021-01-20 연세대학교 산학협력단 위암 오가노이드의 제조 방법

Also Published As

Publication number Publication date
KR20220117170A (ko) 2022-08-23
WO2022177250A3 (fr) 2022-10-13

Similar Documents

Publication Publication Date Title
WO2021208129A1 (fr) Milieu de culture et procédé de culture pour cellules souches épithéliales mammaires
CN108795938A (zh) 肺腺癌外泌体特异miRNA及其靶基因与应用
US5260191A (en) Method for diagnosing tumors
Xu et al. PDCD10 promotes proliferation, migration, and invasion of osteosarcoma by inhibiting apoptosis and activating EMT pathway
CN108504737B (zh) 一种长链非编码rna tralr的应用
Liu et al. CTHRC1 promotes colorectal cancer progression by recruiting tumor-associated macrophages via up-regulation of CCL15
WO2022177250A2 (fr) Organoïdes de cancer de haute pureté et leur procédé de construction
KR20190118702A (ko) 환자 유래 종양세포를 이용한 생체외 조직체 구조물 및 이의 제조방법
CN111057766B (zh) Snhg17在筛选用于调控放射所致肺上皮细胞间质转化和/或肺纤维化的药物中的应用
He et al. The embryonic stem cell microenvironment inhibits mouse glioma cell proliferation by regulating the PI3K/AKT pathway
WO2019103456A2 (fr) Composition de biomarqueur pour diagnostiquer un cancer résistant à la radiothérapie ou pour prédire un pronostic de radiothérapie, contenant de la pmvk en tant que principe actif
CN108531484B (zh) 抑制长链非编码rna tralr制剂的应用
CN111557941A (zh) Plod2的小分子抑制剂米诺地尔在肿瘤治疗中的应用
CN107881240B (zh) 骨肉瘤的诊治标志物
WO2022173212A1 (fr) Modèle animal de cancer invasif du cerveau et son procédé de production
WO2010058974A2 (fr) Méthode pour déterminer collectivement la sensibilité à un médicament thérapeutique contre le cancer
CN115287359B (zh) Mcoln2在结直肠癌中的应用
WO2023277640A1 (fr) Composition pharmaceutique pour le traitement du cancer
WO2023229286A1 (fr) Procédé de fabrication d'un panel d'organoïdes tumoraux personnalisé et système de criblage de médicaments anticancéreux utilisant le panel obtenu selon le procédé
Schrader Role of a single haemopoietic growth factor in multiple proliferative disorders of haemopoietic and related cells
WO2022145532A1 (fr) Biomarqueur pour le pronostic du cancer de l'estomac et son utilisation
CN117187246B (zh) 抑制CKAP5基因表达的siRNA及其应用
WO2019031781A2 (fr) Banque de vecteurs pour criblage à deux hybrides chez la levure et procédé d'identification de liaison d'enzyme de désubiquitination à une protéine cible l'utilisant
WO2023128697A1 (fr) Procédé de culture de sphéroïdes 3d utilisant une lignée cellulaire du cancer du sein et son utilisation
WO2022131667A1 (fr) Composition pharmaceutique pour améliorer l'effet de traitement de mélanome, comprenant un inhibiteur du facteur 2 de transcription des oligodendrocytes en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22756448

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22756448

Country of ref document: EP

Kind code of ref document: A2